Today’s Rating On Watch: Is Benchmark Positive For Heska Corp (HSKA)?

November 29, 2016 - By Clifton Ray

Today's Rating On Watch: Is Benchmark Positive For Heska Corp (HSKA)?

Why Benchmark Gives Heska Corp (HSKA) $78.0 Price Target

Benchmark has started its coverage on Heska Corp (HSKA), today Tuesday, 29 November. The broker finds the stock of HSKA attractive and has price target of $78.0 with “Buy” rating.

About 40,582 shares traded hands. Heska Corp (HSKA) has risen 132.87% since April 26, 2016 and is uptrending. It has outperformed by 127.61% the S&P500.

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on March, 2. They expect $0.37 earnings per share, up 32.14% or $0.09 from last year’s $0.28 per share. HSKA’s profit will be $2.52 million for 45.85 P/E if the $0.37 EPS becomes a reality. After $0.45 actual earnings per share reported by Heska Corp for the previous quarter, Wall Street now forecasts -17.78% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 1.36 in Q2 2016. Its down 0.18, from 1.54 in 2016Q1. The ratio worsened, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.

Pembroke Mngmt accumulated 0.47% or 137,103 shares. Moreover, Wells Fargo & Mn has 0% invested in Heska Corp (NASDAQ:HSKA) for 2,828 shares. Northern Tru Corporation last reported 83,537 shares in the company. Oberweis Asset Mngmt has invested 0.24% of its portfolio in Heska Corp (NASDAQ:HSKA). The United Kingdom-based Oxford Asset has invested 0.09% in Heska Corp (NASDAQ:HSKA). Blackrock Fund Advisors holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 159,181 shares. Adams Diversified Equity Fund Incorporated holds 7,500 shares or 0.02% of its portfolio. Neuberger Berman Gp Ltd Liability last reported 0% of its portfolio in the stock. Us Comml Bank De holds 56,246 shares or 0.01% of its portfolio. Allianz Asset Management Ag accumulated 48,013 shares or 0% of the stock. Moreover, Tower Cap Llc (Trc) has 0% invested in Heska Corp (NASDAQ:HSKA) for 983 shares. Tiaa Cref Management Ltd reported 40,028 shares or 0% of all its holdings. Panagora Asset Mngmt Inc has 0.02% invested in the company for 83,884 shares. Eagle Global Advisors Limited Liability Company accumulated 19,080 shares or 0.02% of the stock. Teton Advsr Incorporated accumulated 0.13% or 38,000 shares.

Insider Transactions: Since July 1, 2016, the stock had 0 insider buys, and 15 insider sales for $6.68 million net activity. $324,258 worth of Heska Corp (NASDAQ:HSKA) was sold by Lippincott Rod on Tuesday, November 22. Wilson Kevin S. also sold $879 worth of Heska Corp (NASDAQ:HSKA) shares. On Monday, November 7 McGinley Michael J sold $601,051 worth of the stock or 9,998 shares. McMahon John sold 137 shares worth $7,028. $820,000 worth of Heska Corp (NASDAQ:HSKA) was sold by NAPOLITANO JASON A on Thursday, July 7. Another trade for 4,698 shares valued at $246,864 was sold by Asakowicz Steve.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The company has a market cap of $463.02 million. The Firm focuses on the canine and feline companion animal health markets. It has a 54.62 P/E ratio. The Company’s divisions include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>